Bioptik Technology Incorporation

Total Valuation

Bioptik Technology Incorporation carries a market capitalization of 1.38B, placing it among publicly traded companies globally. Its enterprise value stands at 1.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bioptik Technology Incorporation currently has 59.81M shares outstanding.

Valuation Ratios

Bioptik Technology Incorporation trades at a trailing price-to-earnings ratio of 20.13. The price-to-sales ratio is 1.71, and the price-to-book ratio stands at 2.13.

Enterprise Valuation

On an enterprise value basis, Bioptik Technology Incorporation trades at an EV/EBITDA multiple of 21.95 and an EV/FCF ratio of 16.40. The EV/Sales ratio of 1.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.95 provides insight into valuation relative to core operating earnings.

Financial Position

Bioptik Technology Incorporation maintains a current ratio of 1.93, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 48.27, indicating elevated leverage, while an interest coverage ratio of 8.74 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Bioptik Technology Incorporation posts a return on equity of 10.97 and a return on invested capital of 3.86.

Taxes

Over the trailing twelve months, Bioptik Technology Incorporation has paid 15.48M in income taxes, reflecting an effective tax rate of 18.14.

Stock Price Statistics

Bioptik Technology Incorporation's stock has declined approximately -15.26045% over the past 52 weeks. The 50-day moving average sits at 23.79, while the 200-day moving average is 25.86.

Income Statement

Over the trailing twelve months, Bioptik Technology Incorporation generated 837.19M in revenue and converted that into 71.19M in net income, yielding earnings per share of 1.31. EBITDA reached 66.54M, while operating income came in at 66.54M.

Balance Sheet

Bioptik Technology Incorporation holds 448.38M in cash and equivalents against 470.47M in total debt, resulting in a net debt position of 68.52M. Total book value stands at 673.71M, with working capital of 451.15M providing operational flexibility.

Cash Flow

Bioptik Technology Incorporation produced 59.99M in operating cash flow over the past twelve months. After subtracting -22.80M in capital expenditures, free cash flow totaled 37.19M - equivalent to 0.65 per share.

Margins

Bioptik Technology Incorporation operates with a gross margin of 29.09, reflecting its pricing power and cost economics. The operating margin of 7.95 and net profit margin of 8.50 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Bioptik Technology Incorporation's most recent stock split took place on August 28, 2023 with a 20:21 split ratio.

Scores

Bioptik Technology Incorporation posts an Altman Z-Score of 2.53, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.